Jazz Pharmaceuticals PLC.
JAZZ
$2.32 (-1.02%)
1D
1W
3M
1Y
5Y
ALL
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 11 days ago • JAZZ
Jazz Pharmaceuticals Q1 Review: The Oncology Pivot Is Real, And The Market Is Still Mispricing It
Zacks Investment Research • 11 days ago • JAZZ
JAZZ Stock Jumps as Q1 Earnings & Sales Surpass Expectations
Seeking Alpha • 12 days ago • JAZZ
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
Zacks Investment Research • 12 days ago • JAZZ
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research • 12 days ago • JAZZ
Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Top Estimates
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.